# Gencurix

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/gencurix

- Industry: Healthcare
- Headquarters: Seoul, South Korea
- Website: www.gencurix.com
- Total disclosed funding: $8.8M
- Latest round: Series B (Sep 21, 2015)
- Investors on record: 4

## About

Founded in 2011 and based in Seoul, South Korea, Gencurix Inc. operates as a medical equipment company that focuses on diagnostic equipment manufacturing. The company established NGeneBio in November 2015. The company passed Korea Good Manufacturing Practice certification in July 2015. The company listed on Kosdaq in June 2020.

The company provides diagnostic solutions, including early cancer diagnosis, prognostic and companion diagnostics and postoperative monitoring. The company's products include GenesWell BCT, Droplex, GenesWell ddEGFR mutation test. Droplex provides as a genetic testing based on digital polymerase chain reaction (PCR) platform. GenesWell ddEGFR mutation test provides diagnostics for lung cancer. The company has molecular diagnostics center, R&D lobaratory, production facility/QC.

## Funding rounds

- Series B, Sep 21, 2015, $6.8M — KB Investment, Partners Investment, Posco Investment
- Series A, Jun 1, 2014, $2M — BNH Investment

## Investors

- BNH Investment (https://capitalatlas.ai/funds/bnh-investment) — Series A
- KB Investment (https://capitalatlas.ai/funds/kb-investment) — Series B
- Partners Investment (https://capitalatlas.ai/funds/partners-investment) — Series B
- Posco Investment (https://capitalatlas.ai/funds/posco-investment) — Series B